GTHX Projected Dividend Yield
G1 Therapeutics Inc ( NASDAQ : GTHX )G1 Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. Co.'s primary compound trilaciclib is a therapy designed to help protect against chemotherapy-induced myelosuppression. Trilaciclib helps protect hematopoietic stem and progenitor cells in the bone marrow by transiently inhibiting CDK4/6 leading to a temporary arrest of susceptible host cells during chemotherapy in patients. Rintodestrant is an oral selective estrogen receptor degrader for the treatment of ER+ breast cancer. 20 YEAR PERFORMANCE RESULTS |
GTHX Dividend History Detail GTHX Dividend News GTHX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |